Peptide-assembled nanoparticles targeting tumor cells and tumor microenvironment for cancer therapy

Zhang, Meichen; Xu, Haiyan

doi:10.3389/fchem.2023.1115495

Cited by 9 publications

(4 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti‐fibrotic agents ( e.g ., sorafenib, pirfenidone, losartan, serelaxin) have been reported to reduce the contents of ECM components and decrease tumor interstitial fibrosis. [ 34‐39 ] Therefore, delivering antifibrotic agents has been proposed effective in enhancing the therapeutic outcome of nanomedicine in stroma‐rich tumors via the combination of anti‐fibrotic and anti‐tumor effect. As an example, Zhang et al .…”

Section: Nanostrategies For Overcoming Stromal Barriersmentioning

confidence: 99%

Nanomedicine Disrupts Stromal Barriers to Augment Drug Penetration for Improved Cancer Therapy^†

Luo,

Chen,

Zhang

2024

Chin. J. Chem.

View full text Add to dashboard Cite

Comprehensive SummaryTumor stroma composing diverse extracellular matrixes (ECM) and stromal cells shapes a condensed physical barrier, which severely hampers the efficient accessibility of nanomedicine to tumor cells, especially these deep‐seated in the core of tumor. Such barrier significantly compromises the antitumor effects of drug‐loaded nanomedicine, revealing the remarkable importance of disrupting stromal barrier for improved tumor therapy with deep penetration ability. To achieve this goal, various nanoparticle‐based strategies have been developed, including direct depleting ECM components via delivering anti‐fibrotic agents or targeting stromal cells to suppress ECM expression, dynamic regulation of nanoparticles’ physicochemical properties (i.e., size, surface charge, and morphology), mechanical force‐driven deep penetration, and natural/biomimetic self‐driven nanomedicine. All these nanostrategies were systemically summarized in this review, and the design principles for obtaining admirable nanomedicine were included. With the rapid development of nanotechnology, elaborate design of multifunctional nanomedicine provides new opportunities for overcoming the critical stromal barriers to maximize the therapeutic index of various therapies, such as chemotherapy, photodynamic therapy, and immunotherapy.This article is protected by copyright. All rights reserved.

show abstract

Section: Nanostrategies For Overcoming Stromal Barriersmentioning

confidence: 99%

Nanomedicine Disrupts Stromal Barriers to Augment Drug Penetration for Improved Cancer Therapy^†

Luo,

Chen,

Zhang

2024

Chin. J. Chem.

View full text Add to dashboard Cite

show abstract

“…Tumortargeting peptides can specifically recognize tumor blood vessels or tumor-related receptors to achieve targeting. With advancing research techniques, many tumor-targeting peptides have been discovered [124,126,[301][302][303][304]. The accumulation of PDCs in tumors and normal organs relies primarily on tumor-targeting peptides, which play a crucial role in molecular targeting.…”

Section: Tumor-targeting Peptidesmentioning

confidence: 99%

Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice

Zhou,

Lu,

Liu

et al. 2024

Exp Hematol Oncol

View full text Add to dashboard Cite

A drug conjugate consists of a cytotoxic drug bound via a linker to a targeted ligand, allowing the targeted delivery of the drug to one or more tumor sites. This approach simultaneously reduces drug toxicity and increases efficacy, with a powerful combination of efficient killing and precise targeting. Antibody‒drug conjugates (ADCs) are the best-known type of drug conjugate, combining the specificity of antibodies with the cytotoxicity of chemotherapeutic drugs to reduce adverse reactions by preferentially targeting the payload to the tumor. The structure of ADCs has also provided inspiration for the development of additional drug conjugates. In recent years, drug conjugates such as ADCs, peptide‒drug conjugates (PDCs) and radionuclide drug conjugates (RDCs) have been approved by the Food and Drug Administration (FDA). The scope and application of drug conjugates have been expanding, including combination therapy and precise drug delivery, and a variety of new conjugation technology concepts have emerged. Additionally, new conjugation technology-based drugs have been developed in industry. In addition to chemotherapy, targeted therapy and immunotherapy, drug conjugate therapy has undergone continuous development and made significant progress in treating lung cancer in recent years, offering a promising strategy for the treatment of this disease. In this review, we discuss recent advances in the use of drug conjugates for lung cancer treatment, including structure-based drug design, mechanisms of action, clinical trials, and side effects. Furthermore, challenges, potential approaches and future prospects are presented.

show abstract

“…Peptides can be designed to self-assemble or be combined with polymeric molecules to create nanoparticles through non-covalent bonds. These nanoparticles have demonstrated attractive properties, including improved recognition of targeted cells, responsiveness to microenvironments, facilitation of internalization, and enhanced therapeutic effects [ 207 ]. X4-2-6, a PEG-modified 24-amino acid peptide analog of the second transmembrane helix of CXCR4, forms nanoparticles that inhibit CXCR4 function, prevent bone metastasis, and serve as a drug delivery system [ 55 ].…”

Section: Peptide Design Strategiesmentioning

confidence: 99%

Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions

Nhàn,

Yamada,

Yamada

2023

IJMS

View full text Add to dashboard Cite

Peptide-based strategies have received an enormous amount of attention because of their specificity and applicability. Their specificity and tumor-targeting ability are applied to diagnosis and treatment for cancer patients. In this review, we will summarize recent advancements and future perspectives on peptide-based strategies for cancer treatment. The literature search was conducted to identify relevant articles for peptide-based strategies for cancer treatment. It was performed using PubMed for articles in English until June 2023. Information on clinical trials was also obtained from ClinicalTrial.gov. Given that peptide-based strategies have several advantages such as targeted delivery to the diseased area, personalized designs, relatively small sizes, and simple production process, bioactive peptides having anti-cancer activities (anti-cancer peptides or ACPs) have been tested in pre-clinical settings and clinical trials. The capability of peptides for tumor targeting is essentially useful for peptide–drug conjugates (PDCs), diagnosis, and image-guided surgery. Immunomodulation with peptide vaccines has been extensively tested in clinical trials. Despite such advantages, FDA-approved peptide agents for solid cancer are still limited. This review will provide a detailed overview of current approaches, design strategies, routes of administration, and new technological advancements. We will highlight the success and limitations of peptide-based therapies for cancer treatment.

show abstract

Peptide-assembled nanoparticles targeting tumor cells and tumor microenvironment for cancer therapy

Cited by 9 publications

References 139 publications

Nanomedicine Disrupts Stromal Barriers to Augment Drug Penetration for Improved Cancer Therapy^†

Nanomedicine Disrupts Stromal Barriers to Augment Drug Penetration for Improved Cancer Therapy^†

Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice

Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions

Contact Info

Product

Resources

About

Peptide-assembled nanoparticles targeting tumor cells and tumor microenvironment for cancer therapy

Cited by 9 publications

References 139 publications

Nanomedicine Disrupts Stromal Barriers to Augment Drug Penetration for Improved Cancer Therapy†

Nanomedicine Disrupts Stromal Barriers to Augment Drug Penetration for Improved Cancer Therapy†

Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice

Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions

Contact Info

Product

Resources

About

Nanomedicine Disrupts Stromal Barriers to Augment Drug Penetration for Improved Cancer Therapy^†

Nanomedicine Disrupts Stromal Barriers to Augment Drug Penetration for Improved Cancer Therapy^†